Corina Kellam

GLP-1 medications have quickly become known for their impact on weight loss and blood sugar control, but a deeper story is emerging. A growing body of research suggests these drugs may also target chronic, low-grade inflammation, a key driver of cardiovascular disease, metabolic dysfunction, and aging itself. Clinical trials hint that their benefits extend beyond weight loss alone, pointing to direct effects on immune pathways and inflammatory signaling. At the same time, recent high-profile trial results remind us that even promising therapies have limits, particularly in complex diseases like Alzheimer’s. So where do GLP-1s truly fit in the future of prevention and longevity? The answer is more nuanced and more interesting than the headlines suggest.